A study to investigate the pharmacokinetics of subcutaneous administration of cefazolin and meropenem

Not Applicable

• Conditions: Subcutaneous antibiotic administration; Infection - Other infectious diseases

• Registration Number: ACTRN12623000577617
• Lead Sponsor: aurens Manning

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-05-25
• Last Update Posted: 5 June 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

18 years of age or over.
Inpatient who is clinically stable, defined as not having been in ICU or having had an emergency response call in the 24 hours prior to enrolment.
Ability to provide informed consent.
Patient must be receiving = 1g of meropenem or = 2g cefazolin daily.
Anticipated to require IV cefazolin or meropenem for at least 48 hours after enrolment.

Exclusion Criteria

•Patients not clinically stable, as defined by being in ICU, having had a MET call in the 24 hours before screening for enrolment.
•Children <18 years
•Patients whose treating team predict will cease meropenem within 48 hours.
•Patients receiving >1g meropenem, or >2g cefazolin per dosing interval.
•Patients also taking medications predicted to interfere with meropenem or cefazolin pharmacokinetics (valproic acid, probenecid)
•Patients unable to give informed consent themselves.

Study & Design

• Study Type: Interventional
• Study Design: Not specified